Allergy

The FDA approved neffy for treating severe allergic reactions in people over 33 kg in August 2024.

This analysis evaluated the long-term follow-up and risks linked to the self-reported penicillin allergy persistence after a successful oral penicillin challenge and allergy label removal.

In this Lungcast episode, Mora and Sadeameli highlight Asthma Action Plans as well as Asthma Peak Weak considerations for children in the new school year.

In this interview, Kim speaks about the significance of the FDA approval of neffy for patients who face the threat of anaphylaxis and other severe allergic reactions.

Mora and Sadreameli join Lungcast to provide a back-to-school health blueprint, including topics like rescue inhalers, vaccination, vaping and air quality.

The FDA approved epinephrine nasal spray (Neffy) for the emergency treatment of allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh at least 30 kg.

These data also suggest that personalized nutritional advice may be necessary for different individuals, due to the clinical diversity and the impact of differences.

These new data were announced by Aquestive Therapeutics and if approved, Anaphylm Sublingual Film could be the first orally-delivered, non-invasive severe allergy treatment.

Chehade reviews key findings from the phase 3 EoE kids trial and how they inform dupilumab’s use in children 1-11 years of age with eosinophilic esophagitis.

After a busy first half to 2024, a number of high-impact FDA decisions await the healthcare industry through December.

These data highlight the results of an international sample of adult patients with allergies to certain food products and caregivers of children with food allergies.

This analysis looked at children 1 to 11 years of age with eosinophilic esophagitis, highlighting the impacts of dupilumab on EoE.

Aquestive Therapeutics announced positive topline data from the trial on June 25, 2024.

Cerceo, Peden, and Ziska joined HCPLive to speak on the imminent threat posed by climate change, highlighting the impact especially on individuals with allergic disease.

In an announcement by Aquestive Therapeutics, these new findings demonstrated the potential of this orally-administered epinephrine treatment.

James Palmer, MD, provides perspective on the FDA's decision to approve fluticasone propionate nasal spray for adults with chronic rhinosinusitis without nasal polyps.

On March 15, 2024, the FDA approval of fluticasone propionate nasal spray marks the first approval in agency history for treatment of chronic rhinosinusitis without nasal polyps.

New data show sensitization among children with allergic contact dermatitis may be significantly influenced by their age and gender, among other demographic details.

Data presented at AAD 2024 hopes to clarify allergen exposure risks during infancy that may increase risk of allergic contact dermatitis.

These new data from BioCryst, presented at AAAAI, suggest that patients treated with berotralstat may see substantial decreases in HAE attacks.

Viaskin milk patch shows promise in cow’s milk allergy, particularly in children aged 2-11 with 300 μg dose, though the other doses examined failed to prove significant benefit.

Twelve evidence-based Key Action Statements were provided for clinicians to guide them in the treatment of patients reporting inhalant allergy symptoms.

In an interview during the 2024 AAAAI conference, Casale addressed his team’s findings regarding epinephrine nasal spray and its effectiveness with regard to exacerbations of urticaria.

Robert Wood, MD, principal investigator of the OUtMATCH trial, offers insight into the trial and its results beyond the primary outcome, with a focus on what it means for patients and providers.

Omalizumab, the only FDA-approved treatment for multiple food allergies, demonstrated significant efficacy in the OUtMATCH trial, with 67% achieving the primary outcome compared to 7% in the placebo group.